Atara Biotherapeutics Statistics
Want to see ATRA full AI Analyst Report?
Atara Biotherapeutics (ATRA) Stock Statistics & Valuation Metrics
Total Valuation
Atara Biotherapeutics has a market cap or net worth of $78.45M. The enterprise value is $170.59M.
- Market Cap
- $78.45M
- Enterprise Value
- $170.59M
Share Statistics
Atara Biotherapeutics has 10,188,438 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 10,188,438
- Owned by Insiders
- 50.47%
- Owned by Institutions
- 9.08%
Financial Efficiency
Atara Biotherapeutics’s return on equity (ROE) is -0.85 and return on invested capital (ROIC) is 222.66%.
- Return on Equity (ROE)
- -0.85
- Return on Assets (ROA)
- 1.62
- Return on Invested Capital (ROIC)
- 222.66%
- Return on Capital Employed (ROCE)
- 6.75
- Revenue Per Employee
- 8.63M
- Profits Per Employee
- 2.33M
- Employee Count
- 14
- Asset Turnover
- 5.97
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Atara Biotherapeutics is -7.62. Atara Biotherapeutics’s PEG ratio is 0.07.
- PE Ratio
- -7.62
- PS Ratio
- 19.79
- PB Ratio
- -3.11
- Price to FCF
- -6.04
- Price to Operating Cash Flow
- -9.09
- PEG Ratio
- 0.07
Income Statement
In the last 12 months, Atara Biotherapeutics had revenue of 120.77M and earned 32.69M in profits. Earnings per share was 2.61.
- Revenue
- 120.77M
- Gross Profit
- 99.56M
- Operating Income
- 35.86M
- Pretax Income
- 32.72M
- Net Income
- 32.69M
- EBITDA
- 38.63M
- Earnings Per Share (EPS)
- 2.61
Cash Flow
In the last 12 months, operating cash flow was -12.99M and capital expenditures 0, giving a free cash flow of -12.99M billion.
- Operating Cash Flow
- -12.99M
- Free Cash Flow
- -12.99M
- Free Cash Flow per Share
- -0.85
Dividends & Yields
Atara Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -16.55%
- Earnings Yield
- -12.38%
Stock Price Statistics
- Beta
- 0.87
- 52-Week Price Change
- -42.49%
- 50-Day Moving Average
- 8.98
- 200-Day Moving Average
- 7.87
- Relative Strength Index (RSI)
- 38.45
- Average Volume (3m)
- 36.32K
Important Dates
Atara Biotherapeutics upcoming earnings date is Mar 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Atara Biotherapeutics as a current ratio of 0.82, with Debt / Equity ratio of -137.13%
- Current Ratio
- 0.82
- Quick Ratio
- 0.82
- Debt to Market Cap
- 0.19
- Net Debt to EBITDA
- 1.15
- Interest Coverage Ratio
- 9.46
Taxes
In the past 12 months, Atara Biotherapeutics has paid 31.00K in taxes.
- Income Tax
- 31.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Atara Biotherapeutics EV to EBITDA ratio is -6.66, with an EV/FCF ratio of -6.47.
- EV to Sales
- 21.18
- EV to EBITDA
- -6.66
- EV to Free Cash Flow
- -6.47
- EV to Operating Cash Flow
- -6.47
Balance Sheet
Atara Biotherapeutics has $9.92M in cash and marketable securities with $9.57M in debt, giving a net cash position of $351.00K billion.
- Cash & Marketable Securities
- $9.92M
- Total Debt
- $9.57M
- Net Cash
- $351.00K
- Net Cash Per Share
- $0.03
- Tangible Book Value Per Share
- -$2.47
Margins
Gross margin is 82.75%, with operating margin of -343.56%, and net profit margin of -368.58%.
- Gross Margin
- 82.75%
- Operating Margin
- -343.56%
- Pretax Margin
- -368.55%
- Net Profit Margin
- -368.58%
- EBITDA Margin
- -317.93%
- EBIT Margin
- -320.25%
Analyst Forecast
The average price target for Atara Biotherapeutics is $15.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $15.50
- Price Target Upside
- 101.30% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- -97.39%
- EPS Growth Forecast
- -155.19%
Scores
- Smart Score
- 8
- AI Score
- 42
